Interleukin-2 and autoimmune disease
Interleukin-2 and autoimmune disease
批准号:
8196707
负责人:
Abul K. Abbas
金额:
$37.86万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-12-01 至 2013-11-30
关键词:
AcuteAddressAffectAntigensApoptoticAutoantigensAutoimmune DiseasesAutoimmune hemolytic anemiaAutoimmunityBiochemicalBiochemical PathwayBiologicalBiologyCD4 Positive T LymphocytesCell physiologyCellsCessation of lifeChronicClonal ExpansionDataDefectDendritic CellsDendritic cell activationDevelopmentDiseaseDoseEffector CellEventExperimental ModelsFailureFoundationsGene ExpressionGenerationsGenesGeneticGraft RejectionGrowth FactorHemolytic AnemiaIL2RA geneImageImmuneImmune System DiseasesImmune responseImmunosuppressive AgentsImmunotherapyIn VitroInbred BALB C MiceInfectionInterferon Type IIInterleukin-2Knock-outKnockout MiceLightLinkLymphoidMaintenanceMemoryModelingMolecularMouse StrainsMusNatural ImmunityNaturePathogenesisPathway interactionsPeripheralPhenotypePlayProductionProtocols documentationRegulationRegulatory T-LymphocyteResearch PersonnelRoleSignal PathwaySignal TransductionStagingStimulusSystemT cell differentiationT cell responseT memory cellT-Cell ActivationT-Cell Activation PathwayT-Cell DevelopmentT-LymphocyteTestingTherapeuticTherapeutic AgentsTherapeutic UsesThymus GlandTransduction GeneTransgenic MiceTransgenic Organismsallograft rejectionautoreactive T cellbasecytokinedeprivationfitnessgraft vs host diseaseimaging modalityin vivointerestmouse modelnovelpathogenpreventprogramsresearch studyresponsesensortranscription factortumortwo-photon
中文摘要
点击翻译按钮获取中文摘要
英文摘要
6. PROJECT SUMMARY/ABSTRACT:
Interleukin-2 (IL-2) is the prototypic T-cell growth factor but elimination of IL-2 results in severe immune
dysregulation and systemic autoimmunity because the obligatory function of this cytokine is to maintain CD4+
CD25+ FoxP3+ regulatory T-lymphocytes (Treg). Defining the role of IL-2 in the maintenance of Treg, and how
effector and memory cells are generated in the absence of IL-2, is fundamental for understanding the biology
of this cytokine and the pathogenesis of diseases caused by its absence (and more generally, by the absence
of Treg), and also for developing optimal strategies for using this cytokine and its antagonists as therapeutic
immune response modifiers. We will address these issues along the following specific aims.
1. What mechanisms underlie the obligatory role of IL-2 in the maintenance of functional Treg? To test the
hypothesis that the obligatory functions of IL-2 are to prevent apoptotic death of Treg and to promote
expression of genes involved in Treg function, we will define the phenotypic and functional characterisitics of
Treg that develop in the periphery and the thymus in the absence of IL-2 signals. We will use the genetic
approach of deleting Bim, the sensor of cytokine deprivation, to generate viable Treg in the absence of IL-2.
We will define the functions of these cells in vitro and in vivo, and analyze the biochemical pathways that are
defective in these cells compared to FoxP3+ cells that develop in the presence of IL-2. Using retroviral gene
transduction, we will examine the biochemical signals that link IL-2 to Treg survival and function, particularly
Akt and Stat5. We will ask if different amounts and duration of IL-2 signal differentially affect efefctor/memory
cells vs Treg, in order to optimize strategies for therapeutic use of IL-2 and its antagonists.
2. What is the role of IL-2 in effector and memory responses, and how do these responses develop in the
absence of IL-2? To test the hypothesis that IL-2 functions to provide activated T-cells the capacity to
overcome Treg control, and responses become IL-2-independent in the absence of Treg, we will compare the
activation of normal and CD25-deficient T-cells in normal recipients and in IL-2/CD25xCD28 double-knockout
Treg-deficient mice we have developed that have a full lymphoid system. We will also define the biochemical
correlates of T-cell activation in the presence and absence of Treg and IL-2. We will examine the early events
after T-cell recognition of antigen in the absence of Treg, using in vivo imaging methods.
3. What is the basis of the immunological disease associated with IL-2 deficiency? The autoimmune
disease of IL-2-knockout BALB/c mice is characterized by rapid-onset hemolytic anemia and
lymphoproliferation, and is associated with markedly enhanced IFN-g production (Th1 responses) and
activation of dendritic cells (DCs). We will define the mechanism of the enhanced T-cell cytokine response and
its contribution to the autoimmune disease, and explore the possibility that DCs are "spontaneously" activated
b5cause of the absence of endogenous Treg.
Thus, this project addresses fundamental issues of the functions of IL-2 and how its dual role in activating
effector/memory responses and Treg is orchestrated. These studies will shed light on the mechanisms of
immune regulation and tolerance, and may help to optimize protocols for the therapeutic uses of IL-2 and its
antagonists.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
FOCIS 2009 - 2013: The 9th through 13th Annual Meetings of the Federation of Clin
-
批准号:8078836
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2009
-
负责人:Abul K. Abbas
-
依托单位:
Stability and Plasticity of Regulatory T Cells
-
批准号:7688823
-
项目类别:
-
资助金额:$19.73万
-
财政年份:2009
-
负责人:Abul K. Abbas
-
依托单位:
FOCIS 2009 - 2013: The 9th through 13th Annual Meetings of the Federation of Clin
-
批准号:8278695
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2009
-
负责人:Abul K. Abbas
-
依托单位:
FOCIS 2009 - 2013: The 9th through 13th Annual Meetings of the Federation of Clin
-
批准号:8470530
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2009
-
负责人:Abul K. Abbas
-
依托单位:
Interleukin-2 and autoimmune disease
-
批准号:7994862
-
项目类别:
-
资助金额:$37.86万
-
财政年份:2007
-
负责人:Abul K. Abbas
-
依托单位:
Interleukin-2 and autoimmune disease
-
批准号:7370244
-
项目类别:
-
资助金额:$38.55万
-
财政年份:2007
-
负责人:Abul K. Abbas
-
依托单位:
13th International Congress of Immunology
-
批准号:7333178
-
项目类别:
-
资助金额:$1.0万
-
财政年份:2007
-
负责人:Abul K. Abbas
-
依托单位:
Interleukin-2 and autoimmune disease
-
批准号:7534357
-
项目类别:
-
资助金额:$38.63万
-
财政年份:2007
-
负责人:Abul K. Abbas
-
依托单位:
Interleukin-2 and autoimmune disease
-
批准号:7740173
-
项目类别:
-
资助金额:$38.24万
-
财政年份:2007
-
负责人:Abul K. Abbas
-
依托单位:
Mechanisms of Peripheral CD4 T-cells tolerance
-
批准号:7215471
-
项目类别:
-
资助金额:$30.75万
-
财政年份:2006
-
负责人:Abul K. Abbas
-
依托单位:
Immunodeficiency and Autoimmunity
-
批准号:7176170
-
项目类别:
-
资助金额:$44.47万
-
财政年份:2005
-
负责人:Abul K. Abbas
-
依托单位:
Immunodefiency and Autoimmunity
-
批准号:7011236
-
项目类别:
-
资助金额:$36.98万
-
财政年份:2005
-
负责人:Abul K. Abbas
-
依托单位:
Immunodeficiency and Autoimmunity
-
批准号:6911877
-
项目类别:
-
资助金额:$37.88万
-
财政年份:2005
-
负责人:Abul K. Abbas
-
依托单位:
Immunodefiency and Autoimmunity
-
批准号:7270255
-
项目类别:
-
资助金额:$2.65万
-
财政年份:2005
-
负责人:Abul K. Abbas
-
依托单位:
Immunodeficiency and Autoimmunity
-
批准号:7346921
-
项目类别:
-
资助金额:$43.46万
-
财政年份:2005
-
负责人:Abul K. Abbas
-
依托单位:
Immunodeficiency and Autoimmunity
-
批准号:7560013
-
项目类别:
-
资助金额:$43.47万
-
财政年份:2005
-
负责人:Abul K. Abbas
-
依托单位:
MECHANISMS OF T CELL TOLERANCE VS AUTOIMMUNITY IN VIVO
-
批准号:6616873
-
项目类别:
-
资助金额:$23.07万
-
财政年份:2002
-
负责人:Abul K. Abbas
-
依托单位:
MEMORY T CELL DEVELOPMENT
-
批准号:6374228
-
项目类别:
-
资助金额:$25.81万
-
财政年份:2000
-
负责人:Abul K. Abbas
-
依托单位:
MEMORY T CELL DEVELOPMENT
-
批准号:6740217
-
项目类别:
-
资助金额:$25.81万
-
财政年份:2000
-
负责人:Abul K. Abbas
-
依托单位:
MEMORY T CELL DEVELOPMENT
-
批准号:6532789
-
项目类别:
-
资助金额:$23.23万
-
财政年份:2000
-
负责人:Abul K. Abbas
-
依托单位:
海外基金